What's new? Log in Free sign up

Metagenomi, Inc. Common Stock (MGX)

Company Profile

Company profile

Ticker

MGX

Exchange

Incorporated

Location

Fiscal year end

Industry (SIC)

Biological Products, (No Diagnostic Substances)

Shinhan Financial • Microsoft • Amgen • Cigna • Energy Transfer • T-Mobile US • Gilead Sciences • Apollo Global Management • MGM Resorts International • Micron Technology ...

SEC CIK

Corporate docs

Material Contracts & Credit Agreements

IRS number

832735153

MGX stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Average target

$13.00

Low target

$7.00

High target

$17.00

Chardan Capital

HC Wainwright & Co.

BMO Capital

Maintains

Outperform

$17.00

15 Aug 24

Latest filings (excl ownership)

View all

Metagenomi Announces Preclinical Data for Lead Hemophilia A Program

Metagenomi Reports Business Updates and Second Quarter 2024 Financial Results

Quarterly report

14 Aug 24

Metagenomi Presents Data at Scientific Conferences and First Quarter 2024 Financial Results

Quarterly report

Nasdaq listed (MGX) Business Update Call May 1st, 2024, 5pm ET Unlocking 4 Billion Years of Microbial Evolution to Create Curative Genetic Medicines

Metagenomi Reports Business Updates and Full Year 2023 Financial Results

Amendments to Articles of Incorporation or Bylaws

Prospectus supplement with pricing info

Latest ownership filings

View all

Sozo Ventures III, L.P.

Juergen Eckhardt

Sarah B. Noonberg

Sebastian Bernales

Financial summary

Financial statements Chart MGX financial data

Quarter (USD)	Jun 24	Mar 24	Dec 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
Cash on hand (at last report)	66.43 mm		66.43 mm
Cash burn (monthly)	13.79 mm		5.62 mm
Cash used (since last report)	57.94 mm		23.61 mm
Cash remaining	8.49 mm		42.82 mm
Runway (months of cash)	0.6		7.6

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q2 2024

MGX institutional ownership history Ownership history

31.0% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	53	0	NEW
Opened positions	53	0	NEW
Closed positions	0	0
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	46.27 bn	0.00	NEW
Total shares	11.61 mm	0.00	NEW
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Novo Holdings A/S	1.80 mm	$7.34 bn	NEW
Ra Capital Management	1.48 mm	$6.03 bn	NEW
Farallon Capital Management	1.34 mm	$5.48 bn	NEW
Partner Fund Management	1.27 mm	$5.17 bn	NEW
Hillhouse Capital Advisors	777.77 k	$3.17 bn	NEW
Citadel Advisors	729.85 k	$2.93 bn	NEW
Eventide Asset Managment	583.04 k	$2.38 bn	NEW
Deep Track Capital	466.23 k	$1.90 bn	NEW
BLK BlackRock	420.24 k	$1.71 bn	NEW
Norges Bank	360.20 k	$1.47 bn	NEW

Largest transactions	Shares	Bought/sold	Change
Novo Holdings A/S	1.80 mm	+1.80 mm	NEW
Ra Capital Management	1.48 mm	+1.48 mm	NEW
Farallon Capital Management	1.34 mm	+1.34 mm	NEW
Partner Fund Management	1.27 mm	+1.27 mm	NEW
Hillhouse Capital Advisors	777.77 k	+777.77 k	NEW
Citadel Advisors	729.85 k	+729.85 k	NEW
Eventide Asset Managment	583.04 k	+583.04 k	NEW
Deep Track Capital	466.23 k	+466.23 k	NEW
BLK BlackRock	420.24 k	+420.24 k	NEW
Norges Bank	360.20 k	+360.20 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

MGX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
5 Sep 24	Pamela Wapnick	Common Stock	Sell	Dispose S	No	No	2.88	6,265	18.04 k	63,051
1 Apr 24	Brian C. Thomas	Common Stock	Grant	Acquire A	No	No	0	118,992	0.00	2,496,276
1 Apr 24	Brian C. Thomas	Stock Option Common Stock	Grant	Acquire A	No	No	10.82	500,323	5.41 mm	500,323
1 Apr 24	Willard H Dere	Stock Option Common Stock	Grant	Acquire A	No	No	10.82	78,636	850.84 k	78,636
1 Apr 24	Simren Delaney	Common Stock	Grant	Acquire A	No	No	0	6,931	0.00	93,892
1 Apr 24	Simren Delaney	Stock Option Common Stock	Grant	Acquire A	No	No	10.82	29,145	315.35 k	29,145
1 Apr 24	Sebastian Bernales	Stock Option Common Stock	Grant	Acquire A	No	No	10.82	78,636	850.84 k	78,636

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

HC Wainwright & Co. Reiterates Buy on Metagenomi, Maintains $7 Price Target

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Metagenomi (NASDAQ:MGX) with a Buy and maintains $7 price target.

Reported Earlier, Metagenomi Shares Data On SMART Gene Editing Platform At AIChE Conference, Emphasizing AAV Packaging

Poster presentation highlights SMART adenine base editors (ABEs) small enough to be packaged into a single adeno-associated virus (AAV) Data demonstrate compact SMART system optimizations allowing

Peeling Back The Layers: Exploring Metagenomi Through Analyst Insights

HC Wainwright & Co. Reiterates Buy on Metagenomi, Maintains $7 Price Target

Chardan Capital Maintains Buy on Metagenomi, Maintains $15 Price Target

Press releases

From Benzinga Pro

MGX Investors Have Opportunity to Lead Metagenomi, Inc. Securities Fraud Lawsuit

BENSALEM, Pa., Nov. 4, 2024 /PRNewswire/ -- Law Offices of Howard G.

Metagenomi, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before November 25, 2024 to Discuss Your Rights – MGX

NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Metagenomi, Inc. ("Metagenomi" or the "Company") (NASDAQ:MGX) of a class action securities lawsuit. CLASS

MGX Investors Have Opportunity to Lead Metagenomi, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES, Nov.

METAGENOMI, INC. (NASDAQ: MGX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Metagenomi, Inc. Investors of Upcoming Deadline

Metagenomi, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before November 25, 2024 to Discuss Your Rights - MGX

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.